The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer

Yasinska, Inna M.; Sakhnevych, Svetlana S.; Pavlova, Ludmila; Teo Hansen Selnø, Anette; Teuscher Abeleira, Ana Maria; Benlaouer, Ouafa; Gonçalves Silva, Isabel; Mosimann, Marianne; Varani, Luca; Bardelli, Marco; Hussain, Rohanah; Siligardi, Giuliano; Cholewa, Dietmar; Berger, Steffen Michael; Gibbs, Bernhard F.; Ushkaryov, Yuri A.; Fasler-Kan, Elizaveta; Klenova, Elena; Sumbayev, Vadim V. (2019). The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer. Frontiers in immunology, 10, p. 1594. Frontiers Research Foundation 10.3389/fimmu.2019.01594

[img]
Preview
Text
fimmu-10-01594.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

Human cancer cells operate a variety of effective molecular and signaling mechanisms which allow them to escape host immune surveillance and thus progress the disease. We have recently reported that the immune receptor Tim-3 and its natural ligand galectin-9 are involved in the immune escape of human acute myeloid leukemia (AML) cells. These cells use the neuronal receptor latrophilin 1 (LPHN1) and its ligand fibronectin leucine rich transmembrane protein 3 (FLRT3, and possibly other ligands) to trigger the pathway. We hypothesized that the Tim-3-galectin-9 pathway may be involved in the immune escape of cancer cells of different origins. We found that studied breast tumors expressed significantly higher levels of both galectin-9 and Tim-3 compared to healthy breast tissues of the same patients and that these proteins were co-localized. Increased levels of LPHN2 and expressions of LPHN3 as well as FLRT3 were also detected in breast tumor cells. Activation of this pathway facilitated the translocation of galectin-9 onto the tumor cell surface, however no secretion of galectin-9 by tumor cells was observed. Surface-based galectin-9 was able to protect breast carcinoma cells against cytotoxic T cell-induced death. Furthermore, we found that cell lines from brain, colorectal, kidney, blood/mast cell, liver, prostate, lung, and skin cancers expressed detectable amounts of both Tim-3 and galectin-9 proteins. The majority of cell lines expressed one of the LPHN isoforms and FLRT3. We conclude that the Tim-3-galectin-9 pathway is operated by a wide range of human cancer cells and is possibly involved in prevention of anti-tumor immunity.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Surgery

UniBE Contributor:

Cholewa, Dietmar; Berger, Steffen Michael and Fasler-Kan, Elizaveta

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1664-3224

Publisher:

Frontiers Research Foundation

Language:

English

Submitter:

Christoph Steffen

Date Deposited:

05 Dec 2019 15:33

Last Modified:

08 Dec 2019 02:46

Publisher DOI:

10.3389/fimmu.2019.01594

PubMed ID:

31354733

BORIS DOI:

10.7892/boris.135427

URI:

https://boris.unibe.ch/id/eprint/135427

Actions (login required)

Edit item Edit item
Provide Feedback